Filamon Limited, an Australian biotech company focused on developing next-gen anti-inflammatory drugs, has announced its breakthrough dementia treatment. ALPHA-003 is designed to preserve the integrity of vital brain cell structures and protect them against destruction caused by brain inflammation.